NMPA Accepts Innovent’s Sintilimab Application for Advanced Melanoma
China’s NMPA accepted an application for a new indication of sintilimab to treat advanced melanoma.
China’s NMPA accepted an application for a new indication of sintilimab to treat advanced melanoma.